Compare NetEase Inc (NTES) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

NetEase (NTES) trades at $119.45, up 0.13% on the day, with a bearish technical signal from moving averages and mixed earnings performance including a Q2 2026 EPS miss. The company maintains strong profitability with a 27.88% net income margin and robust cash flow, though net cash flow turned negative in 2025. Recent news highlights dividend growth and international expansion efforts amid competitive pressures.

The stock presents a valuation opportunity with a P/E of 15.93 below sector averages, supported by an 81.82% analyst buy rating. Key risks include earnings volatility and heavy investing outflows, but solid fundamentals and global growth initiatives offer long-term upside potential for patient investors.

Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.

The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.